Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of Oral Tetrahydrouridine-Decitabine to Treat Relapsed or Refractory Myelodysplastic Syndromes

NCT07006025 is registered in ClinicalTrials.gov with Treebough Therapies as lead sponsor.

NCT NCT07006025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07006025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of Oral Tetrahydrouridine-Decitabine to Treat Relapsed or Refractory Myelodysplastic Syndromes
Lead sponsor
Treebough Therapies
Phase
Phase 1
Overall status
Recruiting
Start date
June 3, 2025
Completion date
March 30, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mds